Volumetric dried blood microsampling for monitoring imatinib mesylate therapy: Method development and clinical application in patients with chronic myeloid leukemia.
Adherence
Chronic myeloid leukemia
Imatinib
Norimatinib
VAMS
Journal
Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Titre abrégé: J Pharm Biomed Anal
Pays: England
ID NLM: 8309336
Informations de publication
Date de publication:
05 Jan 2023
05 Jan 2023
Historique:
received:
09
08
2022
revised:
29
09
2022
accepted:
11
10
2022
pubmed:
25
10
2022
medline:
8
11
2022
entrez:
24
10
2022
Statut:
ppublish
Résumé
Chronic Myeloid Leukemia (CML) is a hematologic neoplasia, characterized as a proliferative disease of the hematopoietic system. Imatinib mesylate (IM), a selective tyrosine kinase inhibitor, is considered a first-line therapy for CML, indicated for both adult and pediatric patients presenting the Philadelphia chromosome (Ph
Identifiants
pubmed: 36279845
pii: S0731-7085(22)00529-5
doi: 10.1016/j.jpba.2022.115108
pii:
doi:
Substances chimiques
Imatinib Mesylate
8A1O1M485B
Protein Kinase Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115108Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.